Related Experiment Videos
Can phosphodiesterase type 5 inhibitors cure erectile dysfunction?
Francesco Montorsi1, Alberto Briganti, Andrea Salonia
1Department of Urology, Università Vita-Salute San Raffaele, Milan, Italy. montorsi.francesco@hsr.it
European Urology
|January 25, 2006
Summary
Chronic use of phosphodiesterase type 5 (PDE-5) inhibitors may improve erectile dysfunction (ED) by enhancing vascular and endothelial function. Animal studies support these benefits, though long-term human data are still needed.
Area of Science:
- Urology
- Pharmacology
- Cardiovascular Science
Background:
- Erectile dysfunction (ED) is a common condition affecting many men.
- Phosphodiesterase type 5 (PDE-5) inhibitors are widely used for ED treatment.
- Understanding the long-term effects of PDE-5 inhibitors is crucial for optimizing ED management.
Purpose of the Study:
- To systematically review evidence on the chronic administration of PDE-5 inhibitors for erectile dysfunction (ED).
- To analyze clinical and basic science data regarding the potential curative role of PDE-5 inhibitors in ED.
Main Methods:
- A comprehensive literature search was conducted using Medline and Cancerlit databases (1993-2005).
- Abstracts from key urology and sexual medicine journals and scientific society proceedings were also assessed.
Main Results:
- Chronic PDE-5 inhibitor use is associated with improved vascular and endothelial function.
- These effects are mediated by increased endothelial cGMP levels, promoting vasodilation.
- Clinical studies and animal models suggest a protective role for PDE-5 inhibitors on endothelial function and penile tissue.
Conclusions:
- Evidence suggests chronic PDE-5 inhibitor administration may improve erectile function in ED patients.
- Long-term human data are limited, but animal studies support potential benefits on endothelial function.
- Further research is warranted to confirm long-term efficacy and safety in humans.